Dynamic susceptibility contrast 19F-MRI of inhaled perfluoropropane: a novel approach to combined pulmonary ventilation and perfusion imaging by Neal MA et al.
Magn Reson Med. 2019;00:1–10.    | 1wileyonlinelibrary.com/journal/mrm
Received: 24 May 2019 | Revised: 12 July 2019 | Accepted: 16 July 2019
DOI: 10.1002/mrm.27933  
F U L L  P A P E R
Dynamic susceptibility contrast 19F‐MRI of inhaled 
perfluoropropane: a novel approach to combined pulmonary 
ventilation and perfusion imaging
Mary A. Neal1,2 |   Benjamin J. Pippard1,2 |   A. John Simpson1,3 |   Peter E. Thelwall1,2
1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
2Newcastle Magnetic Resonance Centre, Newcastle University, Newcastle upon Tyne, United Kingdom
3Respiratory Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine
Mary A. Neal and Benjamin J. Pippard contributed equally to this work. 
Correspondence
Peter E. Thelwall, Newcastle Magnetic 
Resonance Centre, Newcastle University, 
Newcastle upon Tyne, NE4 5PL, United 
Kingdom.
Email: pete.thelwall@newcastle.ac.uk
Funding information
This work was supported by a Medical 
Research Council (MRC) Confidence in 
Concept grant (MC/PC/16054) and a MRC 
Developmental Pathway Funding Scheme 
grant (MR/N018915/1). Human studies 
were sponsored by the Newcastle upon 
Tyne Hospitals NHS Foundation Trust.
Purpose: To assess alveolar perfusion by applying dynamic susceptibility contrast 
MRI to 19F‐MRI of inhaled perfluoropropane (PFP). We hypothesized that passage of 
gadolinium‐based contrast agent (GBCA) through the pulmonary microvasculature 
would reduce magnetic susceptibility differences between water and gas components 
of the lung, elevating the T∗
2
  of PFP.
Methods: Lung‐representative phantoms were constructed of aqueous PFP‐filled 
foams to characterize the impact of aqueous/gas phase magnetic susceptibility 
differences on PFP T∗
2
. Aqueous phase magnetic susceptibility was modulated by 
addition of different concentrations of GBCA. In vivo studies were performed to 
measure the impact of intravenously administered GBCA on the T∗
2
 of inhaled PFP in 
mice (7.0 Tesla) and in healthy volunteers (3.0 Tesla).
Results: Perfluoropropane T∗
2
 was sensitive to modulation of magnetic susceptibility 
difference between gas and water components of the lung, both in phantom models 
and in vivo. Negation of aqueous/gas phase magnetic susceptibility difference was 
achieved in lung‐representative phantoms and in mice, resulting in a ~2 to 3× elevation 
in PFP T∗
2
 (3.7 to 8.5 ms and 0.7 to 2.6 ms, respectively). Human studies demonstrated 
a transient elevation of inhaled PFP T∗
2
 (1.50 to 1.64 ms) during passage of GBCA 
bolus through the lung circulation, demonstrating sensitivity to lung perfusion.
Conclusion: We demonstrate indirect detection of a GBCA in the pulmonary 
microvasculature via changes to the T∗
2
 of gas phase PFP within directly adjacent 
alveoli. This approach holds potential for assessing alveolar perfusion by dynamic 
susceptibility contrast 19F‐MRI of inhaled PFP, with concurrent assessment of lung 
ventilation properties, relevant to lung physiology and disease.
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1 |  INTRODUCTION
The lungs present challenges for diagnostic MRI due to low 
tissue water content, respiratory and cardiac motion, and 
magnetic field inhomogeneity arising from differences in 
magnetic susceptibility at ubiquitous air–tissue interfaces.1 
The development of hyperpolarized 3He and 129Xe gas MRI 
has addressed some of these challenges to provide quanti-
tative assessment of regional gas distribution and wash‐out 
dynamics in a variety of pulmonary disorders.2-5 However, 
the requirement for polarizing equipment and expertise has 
largely restricted this technique to research settings and spe-
cialist centers. An alternative approach involving 19F‐MRI 
of inhaled perfluoropropane (PFP) has shown potential 
for assessing ventilation properties in healthy volunteers 
and patients with respiratory disease,6-9 building on exten-
sive preclinical10-14 and ex vivo15 studies. PFP has a short 
in vivo T1 (approximately 12 ms at 3.0 Telsa [T]7) that en-
ables a short TR and high degree of signal averaging. This, 
in concert with its 6 magnetically equivalent 19F nuclei per 
molecule and inert nature (permitting inhalation at high con-
centrations), facilitates in vivo imaging of PFP at thermal 
polarization, avoiding the need for hyperpolarization with a 
resultant technical simplicity that offers potential for clinical 
application.
The PFP molecule is substantially larger than 3He and 129Xe 
atoms and has a significantly slower diffusion coefficient (0.07 
cm2/s,16 compared to diffusion coefficients in air of 0.88 cm2/s17 
and 0.14 cm2/s18 for 3He and 129Xe, respectively). Its fluorine 
resonances exhibit a short in vivo T∗
2
 (approximately 2 ms on 
inspiration at 3.0 T,7 compared to 14 ms19 and 24 ms20 for 3He 
and 129Xe, respectively) with limited motional narrowing com-
pared to 3He and 129Xe, where faster diffusion through alveolar 
magnetic susceptibility gradients limits shortening of T∗
2
. The 
resultant sensitivity of PFP T∗
2
 to the lung magnetic microenvi-
ronment presents some technical challenges for MRI of inhaled 
PFP; however, it also provides opportunities to report on lung 
tissue functional properties that include monitoring lung perfu-
sion via alteration of pulmonary magnetic susceptibility gradi-
ents. Modulation of tissue magnetic susceptibility through the 
introduction of a gadolinium‐based contrast agent (GBCA), 
with consequent change in T∗
2
, forms the basis of dynamic 
susceptibility contrast (DSC) MRI. This well‐ established 
technique has been used most widely in the assessment of brain 
perfusion where the paramagnetic properties of intravenously 
administered GBCA cause increased heterogeneity of tissue 
magnetic susceptibility in perfused regions, reducing the T∗
2
 of 
tissue water.21-23
We hypothesized that the magnetic field heterogene-
ity of the lung could be reduced by the presence of a para-
magnetic GBCA in the pulmonary circulation, bringing the 
magnetic susceptibilities of aqueous and gas components 
of the lung closer together as the paramagnetic nature of 
gadolinium counters the diamagnetic properties of tissue 
water. Specifically, we tested whether contrast agent bolus 
passage through the lung microvasculature would result in 
a transient elevation of the T∗
2
 of inhaled PFP, utilizing lung‐
representative phantoms, preclinical models, and subsequent 
demonstration of feasibility in healthy human volunteers. Our 
approach builds on previous preclinical demonstrations of 
reducing lung magnetic susceptibility gradients using para-
magnetic and superparamagnetic contrast agents with hy-
perpolarized 3He‐MRI24,25 by employing PFP as a gas phase 
imaging agent to perform dynamic measurement of suscep-
tibility contrast and by translating this approach to humans.
2 |  METHODS
2.1 | Phantom study
Lung‐representative phantoms (n = 36) were constructed 
of stable aqueous foams. The gas phase of the foams con-
tained a 79:21 ratio mixture of PFP and oxygen, and the 
aqueous phase comprised an aqueous ovalbumin solution 
(1:6 weight/weight ratio of pasteurized egg white powder 
(Dr. Oetker Ltd., UK) and water). Foam was produced by 
repeatedly passing gas and aqueous components between 
a pair of syringes through a 2 mm diameter restriction 
until a stable and homogenous foam was formed (typically 
achieved after 20 passages). Foam volume was 15 mL 
for all samples. Digital photomicrographs were acquired 
with a microscope (Celestron LLC, Torrance, CA) from a 
sample of each of the foams placed on a microscope slide 
immediately prior to MR acquisitions. Mean bubble diam-
eter was measured manually from photomicrographs using 
ImageJ26 from approximately 100 bubbles within the FOV 
of each sample image. The magnetic susceptibility of the 
aqueous component was altered by the addition of a GBCA 
(Gadobutrol, Bayer Schering Pharma, UK) at 12 different 
concentrations over the range 0 to 70 mM, with 3 phan-
toms prepared at each concentration. Three gas‐only sam-
ples (i.e., containing the PFP/oxygen gas mixture alone, 
with no aqueous component) were also prepared for com-
parison. 19F‐MR data were acquired from foam phantoms 
and gas‐only samples with a Philips Achieva 3.0 T scanner 
(Philips, Best, The Netherlands) equipped with a custom 
25 mm diameter 6‐turn solenoid 19F coil, using a pulse‐ 
acquire sequence (TR = 34 ms; flip angle = 90°; acquisi-
tion bandwidth (BW) = 8 kHz; number of datapoints = 256; 
number of averages = 10). The T∗
2
 of PFP was determined 
by fitting Equation 1 to the magnitude of the 19F pulse‐ 
acquire free induction decay, where the equation describes 
monoexponential decay of the 19F signal plus the mean 
magnitude of baseline noise in the FID.
(1)S=
(
S
0
×e−t∕T
∗
2
)
+c.
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A simple model was used to describe the relationship be-
tween difference in magnetic susceptibility between gas and 
aqueous components of the foam and the resultant change 
in T∗
2
. The magnetic susceptibility of the aqueous phase of 
the foam was defined as the sum of magnetic susceptibilities 
of water and GBCA components. The absolute value of the 
difference in magnetic susceptibility between gas and aque-
ous components, Δχ, was calculated using Equation 2, where 
χgas = 0.4 ppm, χaq = −9.05 ppm,27 the molar magnetic sus-
ceptibility of GBCA (χmGd) = 320 ppm L mol−1,28 and CGBCA 
is the concentration of GBCA in the aqueous component of 
the foam.
The relationship between Δχ and change in PFP trans-
verse relaxation rate (ΔR∗
2
) was modeled on the relationship 
observed in and used for analysis of brain DSC 1H‐MRI 
data,22 where ΔR∗
2
 is linearly proportional to Δχ resultant 
from contrast agent administration. Equation 3 describes this 
relationship, where k is a proportionality constant dependent 
on foam microstructural properties and the diffusion coeffi-
cient of PFP that links the magnitude of Δχ to the magnitude 
of PFP ΔR∗
2
.21,22,29 Equation 3 was fitted to PFP R∗
2
 measure-
ments made from phantoms.
2.2 | Preclinical study
Preclinical experiments were performed under a project 
license granted by the UK Home Office in accordance 
with the Animals (Scientific Procedures) Act 1986. Four 
male C57BL/6 mice were anaesthetized by intraperitoneal 
injection of a hypnorm/midazolam/water mixture (1:1:2 
volume ratio, dose 10 mL/kg body weight). A tail vein 
cannula was sited for administration of GBCA (Gadobutrol, 
Bayer Schering Pharma). A custom breathing mask was 
positioned over the mouse head, allowing delivery of a 79% 
PFP/21% oxygen gas mixture (BOC Ltd., Guildford, UK). 
MR data were acquired using a Varian 7.0 T spectrometer 
and console (DirectDrive system, Varian, Palo Alto, CA) 
and a custom 38 mm diameter 19F birdcage coil. Respiratory 
rate and body temperature were monitored throughout 
the study, with body temperature maintained using an air 
heater.
Mice inhaled the PFP/oxygen gas mixture for 1 min prior 
to and during MR scans to measure PFP T∗
2
, which comprised 
a 2D spoiled gradient echo imaging sequence with multiple 
repetitions at different TEs (flip angle = 90o; BW = 50 kHz; 
TE = 1.0, 1.2, 1.4, 1.6, 1.8 ms; TR = 4.0 ms; FOV = 50 × 50 mm2; 
acquisition matrix = 64 × 64; number of averages = 200; 
scan duration = 256 s). The 5 scans with different echo time 
were acquired in an interleaved manner without respiratory 
gating such that the resultant relaxation time measurements 
represent an average over the scan acquisition duration. PFP 
T
∗
2
 measurements were performed prior to and at 3.5 min 
after each of 5 intravenous administrations of Gadobutrol 
(Bayer Schering Pharma) (1M; 200 μL per administra-
tion). The time interval between respective administra-
tions was approximately 5 min (mean ± SD = 307 ± 17 s). 
Mice were removed from the scanner on completion of MR 
imaging and euthanized by cervical dislocation while still 
under anaesthesia.
PFP T∗
2
 was calculated from a 4 × 4 mm2 region of interest 
in the center of the left lung of each mouse by fitting a mono-
exponential function to the decay in 19F signal intensity with 
increasing TE.
2.3 | Human study
This study was reviewed by the National Health Service 
National Research Ethics Service and approved by the National 
Health Service Health Research Authority. Four healthy vol-
unteers (3 males, aged 24, 28, and 34 years; 1 female, aged 
28 years) provided written informed consent to participate 
and were screened for study eligibility, including normal lung 
function assessed by spirometry. All participants were non-
smokers (2 never‐smokers; 2 previous social smokers, each 
with < 1 pack years) and in good health, with no history of 
respiratory, cardiac, or other significant medical problems.
Imaging was performed using a Philips Achieva 3.0 T 
MRI scanner equipped with a 20 cm diameter 19F surface coil 
(PulseTeq Ltd., Woking, UK) for 19F‐MRI acquisitions. A can-
nula was sited in an antecubital fossa vein for intravenous con-
trast administration. Participants were positioned supine with 
the surface coil placed centrally below their upper back such 
that the top of the coil was aligned with the clavicles. Heart rate 
and oxygen saturations were monitored throughout via a MR‐ 
compatible pulse oximeter (Nonin 7500FO, Nonin Medical 
Inc., Plymouth, MA). Scout 1H‐MR images (coronal views) 
were acquired using the scanner’s body coil with a multislice 
2D gradient echo sequence (flip angle = 10°; TE = 1.8 ms; 
TR = 4.0 ms; BW = 450 Hz/pixel; FOV = 450 × 450 × 
250 mm3; acquisition matrix = 192 × 96; scan duration = 26 s).
Participants were instructed to inhale a mixture of 79% 
PFP/21% oxygen (BOC Ltd, Guildford, UK) from a 25 L 
reservoir bag via a mouthpiece and 3‐way valve. Each par-
ticipant performed 3 deep breaths of the gas mixture, fol-
lowed by a 30 s breath‐hold at maximal inspiration (i.e., total 
lung capacity). Gadobutrol (Gadovist 1.0 mmol/mL, Bayer 
Schering Pharma) was administered at a dose of 0.2 mL/kg 
(0.2 mmol/kg equivalent) according to participant weight via 
a power injector (rate = 5 mL/s) concurrent with the start 
of the breath‐hold, followed by a 20 mL saline flush at the 
(2)Δ휒 = |||
(
휒
gas
−
(
휒
aq
+
(
휒
Gd
m
×CGBCA
)))||| .
(3)ΔR∗2= k× Δ휒 .
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same rate. Dynamic 19F‐MR data acquisitions commenced 
immediately prior to the start of the breath‐hold. Breath‐
hold compliance was confirmed by participant observation. 
On completion of the breath‐hold, participants reverted to 
breathing room air.
For the first participant, a dynamic unlocalized 19F pulse‐
acquire FID (flip angle = 90°; BW = 8000 Hz; TR = 250 ms; 
number of datapoints = 256; number of dynamics = 350; 
scan duration = 88 s) was acquired on 2 occasions during 
the scan session: once without and once with concurrent ad-
ministration of GBCA. For the remaining 3 participants, a 
dynamic 19F 2D spoiled gradient echo imaging sequence (flip 
angle = 50°; TE = 1.7 ms; TR = 4.2 ms; BW = 500 Hz/pixel; 
FOV = 300 × 300 × 200 mm3; acquisition matrix = 24 × 24; 
number of dynamics = 600; scan duration = 60 s) was ac-
quired. Dynamic 19F‐MR spectroscopy data were analyzed 
by fitting Equation 1 to the amplitude of the 19F free induc-
tion decay, allowing calculation of PFP T∗
2
 for each repetition 
of the dynamic acquisition. Baseline R∗
2
 was calculated from 
the mean R∗
2
 over the first 7 s of the experimental timecourse, 
and the change in R∗
2
 (i.e., ΔR∗
2
) was calculated for each point 
in the timecourse. Images in the dynamic 19F‐MRI dataset 
were averaged to a temporal resolution of 3 s (i.e., 30 dynam-
ics per average), and the change in 19F signal amplitude over 
the dynamic scan series was calculated on a pixelwise basis 
relative to baseline signal amplitude (defined as the first 7.5 s 
of data acquisition, prior to arrival of GBCA in the pulmo-
nary circulation).
3 |  RESULTS
3.1 | Lung‐representative phantoms
PFP foams had a bubble diameter of 29 ± 12 µm (mean ± SD), 
which was unaffected by the addition of GBCA. PFP‐filled 
aqueous foams containing no GBCA exhibited a shorter T∗
2
 
than that of gas‐only samples (3.7 ± 0.1 ms compared to 9.1 ± 
0.1 ms, respectively). Figure 1A shows the change in PFP T∗
2
 
at 3.0 T as GBCA concentration in the aqueous component 
of the foam was increased. Measured PFP T∗
2
 reached a maxi-
mum of 8.5 ± 0.2 ms at a GBCA concentration of 29 mM, 
where the magnetic susceptibility of the aqueous component 
matches that of the gas component (Δχ = 0). Increasing the 
concentration of GBCA further caused a reduction in PFP T∗
2
 
as magnetic susceptibilities of the aqueous and gas compo-
nents diverged. Figure 1B shows a linear increase in PFP R∗
2
 
as the absolute value of Δχ increases away from this match 
point. Solid lines represent a fit of Equations 2 and 3 to the 
measurements, which yield a calculated T∗
2
 of 9.5 ms at Δχ = 0, 
comparable to the measured T∗
2
 of gas‐only samples (9.1 ± 
0.1 ms). Whilst it is likely that the presence of ovalbumin 
in the aqueous component of the foam altered its magnetic 
susceptibility away from the literature value of χaq used to 
fit Equations 2 and 3 to the data, the agreement between 
inflection points of data and fit suggest that the change in χaq 
away from −9.05ppm was minor. 95% confidence intervals 
for T∗
2
 fits calculated for datapoints shown in Figure 1A,B 
yield error bars within the datapoint markers. Figure 1C 
shows the magnitude of 19F FID signal amplitudes for a gas‐
only sample and for foam samples containing 0 and 30 mM 
GBCA (black lines), as well as fits to the data from which 
T
∗
2
 values were determined (gray lines). The plots show T∗
2
 
relaxation exhibiting slight deviation from exponential decay.
3.2 | Preclinical study
Figure 2A shows a representative gradient echo 19F‐MR image 
acquired from a mouse, overlaid on a 1H anatomical scan. 
A region of analysis for 19F signal amplitude determination 
is shown in blue. Figure 2B shows change in 19F signal 
amplitude with TE measured in a mouse (mouse 1) prior to 
and after administration of 400 µL of GBCA, illustrating the 
F I G U R E  1  Impact of GBCA on the T∗
2
 (A) and R∗
2
 (B) of PFP in a lung‐representative phantom (aqueous foam) with increasing GBCA 
content within the aqueous component of foam samples (•) and model fit to the data (—). The magnetic susceptibilities of aqueous and gas 
components are matched at a GBCA concentration of 29.3 mM. The transverse relaxation rate of PFP increases linearly with change in GBCA 
concentration from this susceptibility match point. (C) FID signal amplitudes for a gas‐only sample and for foam samples containing 0 and 
30 mM GBCA (black lines), and model fits to the data (gray lines). FID, free induction decay; GBCA, gadolinium‐based contrast agent; PFP, 
perfluoropropane
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resultant change in PFP T∗
2
. Figure 2C shows the change in 
in vivo T∗
2
 of inhaled PFP in mouse lung (n = 4) at 7.0 T 
following successive administrations of GBCA. As with lung‐ 
representative phantoms, an increase in PFP T∗
2
 is observed 
from an initial value of 0.7 ± 0.1 ms (mean ± SD) to a 
maximum value 2.6 ± 0.6 ms following administration of 
a total of 400 µL of contrast agent. A decrease in PFP T∗
2
 
was observed with further GBCA administration as magnetic 
susceptibilities of lung tissue and gas components diverge. 
Slight differences in the volume of GBCA required for 
maximal impact on PFP T∗
2
 were observed between mice. 
Body weight varied slightly between animals (30.0, 29.3, 
32.1, and 27.7 g for mice 1 to 4, respectively), which may 
have contributed to this difference.
3.3 | Human study
PFP gas inhalation and intravenous GBCA administration 
were well tolerated by all participants, with no adverse 
events. The mean volume of Gadobutrol administered was 
14.1 mL (range 11.6 to 17.0 mL), determined by participant 
weight (range 58 to 84 kg) and dose (0.2 mL/kg).
Figure 3A shows the in vivo T∗
2
 of inhaled PFP during 
a breath‐hold without GBCA administration, measured by 
19F‐MR spectroscopy in 1 participant. PFP T∗
2
 was 1.54 ± 
0.05 ms (mean ± SD) over the 30 s breath‐hold. Figure 3B 
shows PFP T∗
2
 in the same participant prior to, during, and 
following GBCA bolus passage through the pulmonary vas-
culature. Baseline T∗
2
 prior to GBCA bolus arrival was 1.50 ± 
0.01 ms. Maximal T∗
2
 measured during GBCA bolus pas-
sage through the lungs was 1.64 ms, occurring at 11.25 s. 
The pre‐GBCA T∗
2
 seen in Figure 3B differs slightly from 
the T∗
2
 seen in Figure 3A. We attribute this to slight differ-
ences in lung inflation level between the 2 scans. A subtle 
increase in PFP T∗
2
 was observed over the breath‐hold du-
ration in Figure 3A. Whilst we have not investigated the 
origins of this change, one hypothesis would be that this 
occurs as a result of progressive deoxygenation of the lung 
gas phase during the breath‐hold. Pulse oximetry measure-
ments showed no change in blood oxygen saturation over 
the experiment.
Figure 3C shows change in PFP R∗
2
 over the experimen-
tal time‐course, calculated by comparison to R∗
2
 at baseline, 
showing an elevation in R∗
2
 during GBCA bolus passage 
though the lungs. Figure 3D plots the 19F FID signal mag-
nitude of a single dynamic from the 19F spectroscopy series 
(black line). The fit of a decaying exponential function to 
these data is shown by the gray line from which measured T∗
2
 
was determined. As with foam samples, slight deviation from 
the exponential decay was observed.
Figure 4A shows baseline T∗
2
‐weighted 19F‐MR scans (i.e., 
prior to arrival of the GBCA bolus, generated by averaging 
the initial 75 dynamics of the 19F scan series) overlaid on 
anatomical 1H scans for each of the remaining 3 participants. 
F I G U R E  2  (A) Representative 
gradient echo 19F‐MRI image of inhaled 
PFP acquired from a mouse (colormap), 
overlaid on a 1H‐MRI anatomical image 
(grayscale). Signal amplitude measurements 
made from lung regions of interest (example 
shown in blue) were used for calculation 
of T∗
2
 values. (B) Change in PFP signal 
amplitude with increasing TE (•) measured 
from a lung region of interest in a mouse 
(mouse 1) prior to and after administration 
of 200 µL of contrast agent. (C) Impact 
of intravenous GBCA administration on 
the T∗
2
 of inhaled PFP in 4 mice. Error 
bars show 95% confidence intervals of 
exponential fits to the data. T∗
2
 is maximal 
when the magnetic susceptibilities of lung 
water and gas components are matched, 
following administration and equilibration 
of approximately 400 µL of contrast agent
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Positioning of the 19F surface coil is represented by blue cir-
cles. Figure 4B shows the relative change in PFP signal in-
tensity calculated from dynamic T∗
2
‐weighted 19F‐MRI scans 
following GBCA administration in each participant. A tran-
sient increase in PFP signal intensity of 8.7% ± 2.1% was 
observed at approximately 8 to 14 s following injection of 
Gadobutrol. Data from participant 4 has lower 19F signal to 
noise ratio than data from participants 2 and 3 as a result 
of poor coil positioning. Plots of 19F signal amplitude over 
the experimental timecourse for each participant are shown 
in Figure 5.
4 |  DISCUSSION
We have demonstrated a method for assessing lung perfu-
sion properties by employing an intravenously administered 
GBCA to alter the magnetic susceptibility of pulmonary 
blood directly adjacent to PFP gas within the alveoli. To our 
knowledge, this represents the first in man demonstration of 
DSC 19F‐MRI assessment of pulmonary perfusion using an 
approach that is well suited to concurrent 19F‐MRI of lung 
ventilation within a short breath‐hold duration.
Previous 19F‐MRI studies have reported the ability to 
assess ventilation properties using inert fluorinated gases 
in humans6-8 and in preclinical10-14 and ex vivo models,15 
demonstrating technical feasibility and enabling character-
ization of the physical and MR properties of in vivo fluo-
rocarbon gases.30,31 The signal‐to‐noise ratio and resultant 
image quality of 19F‐MRI of inhaled PFP is inherently lower 
than MRI of hyperpolarized 3He or 129Xe due to its thermal 
polarization. However, the avoidance of hyperpolarization 
facilitates dynamic imaging because PFP signal intensity is 
determined solely by gas concentration and relaxation prop-
erties and without confounding factors arising from T1‐ and 
excitation‐mediated loss of hyperpolarization between scans 
in a dynamic series.
Our studies demonstrate sensitivity of 19F‐MRI to pulmo-
nary perfusion by DSC‐MRI. However, unlike the diminish-
ing effect on T∗
2
 that is observed in conventional 1H DSC‐MRI 
F I G U R E  3  Dynamic measurement of the T∗
2
 of inhaled PFP in a healthy participant during a 30 s breath‐hold without (A) and with (B) 
concurrent intravenous administration of GBCA. PFP T∗
2
 is transiently elevated as the GBCA bolus passes through the pulmonary vasculature 
(highlighted region). (C) Change in PFP R∗
2
 over the experimental time‐course, calculated relative to baseline R∗
2
 prior to GBCA bolus arrival.  
(D) Plot of FID signal magnitude (black line) and an exponential fit to the data (gray line) from a single dynamic of the 19F spectroscopy series
F I G U R E  4  Dynamic 19F‐MRI of inhaled PFP acquired before, during, and after passage of a GBCA bolus through the pulmonary vasculature 
in 3 healthy volunteers. T∗
2
‐weighted 19F‐MRI images overlaid on 1H anatomical scans (left) show blue circles to indicate position of the 19F surface 
coil. Dynamic 19F‐MRI data (right) show relative change in T∗
2
‐weighted 19F‐MRI signal compared to baseline amplitude (i.e., pre‐GBCA bolus 
arrival). A transient elevation in PFP signal amplitude is observed at approximately 8 to 14 s following GBCA administration, reflecting partial 
susceptibility matching of lung water and gas components
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of the brain,21 DSC 19F‐MRI causes an elevation of PFP T∗
2
 
during GBCA bolus passage. This positive contrast is a direct 
consequence of the paramagnetic GBCA reducing lung Δχ 
between adjacent gas and tissue components within the lung, 
an effect that has been reported in previous preclinical stud-
ies. Vignaud et al24 demonstrated a 3‐fold elevation of the T∗
2
 
of inhaled hyperpolarized 3He following intravenous admin-
istration of superparamagnetic iron oxide contrast agent in 
rats. Similarly, Dimitrov et al25 demonstrated partial suscep-
tibility matching of water and gas components in in vivo pig 
lungs following administration of a GBCA, observed in the 
phase shift of 3He gradient echo images. However, neither 
study performed dynamic imaging to assess lung perfusion. 
Vignaud et al. employed imaging once the contrast agent was 
equilibrated throughout body tissues, whereas Dimitrov et al. 
performed separate 3He inhalations for pre‐ and post‐GBCA 
imaging, confounding a direct comparison and thus quantita-
tion of lung perfusion properties. Nonetheless, both studies 
showed that partial or complete susceptibility matching can 
be achieved in the lungs. Our study data are consistent with 
these previous findings and extend this concept to human im-
aging using a DSC approach, drawing on the high sensitivity 
of PFP T∗
2
 to lung microstructural properties. Additionally, 
our studies in lung‐representative phantoms demonstrate the 
linear relationship between contrast agent concentration and 
PFP R∗
2
 in situations in which tissue microstructure is con-
stant (i.e., the value of k in Equation 3 remains unchanged). 
This permits quantitation of relative contrast agent content 
in the lung‐representative phantoms. Whilst k may reason-
ably be expected to remain constant over the breath‐hold 
duration in our human studies, it remains unknown and is 
dependent on tissue microstructural properties. Thus, it is 
possible that k may vary across the lung and indeed with 
underlying pathology, which may confound quantitation of 
relative contrast agent concentration in vivo. Investigating the 
relationship between tissue microstructure and k may provide 
an opportunity to extend analysis to a more quantitative ap-
proach in the future in vitro and in vivo studies. Applying the 
approach to the study of respiratory disease, for example in 
patients with perfusion defects, would be of value to assess 
the impact of pathology on the magnitude of change in con-
trast agent concentration over time as well as on the timing of 
bolus arrival relative to administration within the microvas-
culature adjacent to alveolar gas.
The baseline PFP T∗
2
 values measured in our preclin-
ical studies were shorter than the T∗
2
 values obtained from 
our PFP foam samples and human studies. This reflects the 
higher field strength used (7.0 T for preclinical studies; 3.0 T 
for foam and human studies), with greater resultant magnetic 
susceptibility‐induced field gradients within the lung paren-
chyma at higher field strength. 19F‐MRI of inhaled PFP has 
been successfully applied at 1.5 T, where PFP T∗
2
 is longer 
due to weaker field gradients within the lung.8 The slower T∗
2
 
relaxation may confer an advantage for conventional and DSC 
19F‐MRI of inhaled PFP alongside the advantages of lower RF 
power deposition (specific absorption rate, SAR) in these high 
flip angle, short TR protocols. However, lower field also con-
fers lower thermal polarization and thus lower signal ampli-
tude. A comprehensive comparison of inhaled PFP 19F‐MRI 
performance at 1.5 T and 3.0 T would be of value in deter-
mining optimal MR scanner hardware configuration for this 
application.
Lung inflation level is known to impact the T∗
2
 of inhaled 
PFP.32 Participants in our human studies were instructed to 
perform breath‐holds at full inspiration during 19F‐MRI data 
acquisition to prevent changes in inflation level confound-
ing the measured effects of GBCA on PFP T∗
2
. The data in 
Figure 3B show slightly higher T∗
2
 after GBCA bolus passage 
through the lung vasculature compared to the pre‐GBCA 
baseline T∗
2
. This may arise from extravasation of GBCA 
from the pulmonary vasculature during bolus passage. PFP 
T
∗
2
 relaxation deviated from monoexponential decay in both 
foam and in vivo studies, evident in the early timepoints of 
the FID (0 to 3 ms) shown in Figure 3D. This deviation is 
similar to that observed in 3He studies of rat lung following 
intravenous administration of iron oxide nanoparticles to 
alter aqueous phase magnetic susceptibility.24 This effect has 
been attributed to the structural complexity of lung tissue, 
where magnetic susceptibility gradients occur over a range 
of length scales and across a range of diffusion restriction di-
mensions. Slight deviation from monoexponential decay was 
also observed in the gas‐only sample. Imperfect B0 homoge-
neity may have contributed to nonmonoexponential T∗
2
 decay 
in this sample as well as in foam samples and human studies.
The use of a 19F surface coil for detection of inhaled PFP 
in our human studies prevented imaging of the entire lung 
F I G U R E  5  Amplitude of lung 19F signal from dynamic T∗
2
‐weighted 19F‐MRI scans acquired from participants 2, 3, and 4. An 
elevation in PFP signal amplitude is observed at approximately 8 to 
14 s following GBCA administration, reflecting partial susceptibility 
matching of lung water and gas components
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volume but was nonetheless sufficient to demonstrate techni-
cal feasibility of our approach. Previous studies have demon-
strated visualization of the entire lung volume with inhaled 
PFP.6-8 Further optimization of 19F scan performance through 
the use of multichannel RF coil arrays,8,33 as well as scan 
protocol acceleration with compressed sensing,34 offer poten-
tial to implement dynamic 3D 19F‐MRI. This has clear im-
plications for performing concurrent whole‐lung assessment 
of regional lung ventilation and perfusion through scanner 
hardware and acquisition improvements that can be adopted 
with relative technical simplicity.
Lung‐representative phantoms based on aqueous foams 
provided a valuable physical model to probe the impact of 
altering aqueous component magnetic susceptibility on the 
T
∗
2
 of PFP within the gas phase of the foam. While our foam 
bubble diameters were smaller than typical human alveoli 
(~200 m35), good agreement was observed between the the-
oretical and measured relationship between GBCA content 
and PFP T∗
2
.
GBCAs are an essential tool in diagnostic MRI36 but have 
been associated with side effects such as the development of 
nephrogenic systemic fibrosis and the potential for accumu-
lation of gadolinium within the brain. Our heathy volunteer 
study employed a well‐established GBCA at a dose consis-
tent with current clinical guidelines.37 By comparison, our 
preclinical study used GBCA doses that were considerably 
higher than those used in our human experiments. This re-
flects the acquisition of preclinical data following equilibra-
tion of contrast agent through the mouse circulation (rather 
than employing dynamic visualization of contrast agent bolus 
passage through the pulmonary circulation) and an experi-
mental design to observe complete matching of gas and aque-
ous component magnetic susceptibilities. It is quite feasible 
that a lower GBCA dose could be employed in future human 
19F‐MRI DSC studies given the magnitude of change in R∗
2
 
observed. Furthermore, the use of GBCA in this setting can 
be considered in the context of current clinical methods to 
assess lung perfusion (namely, planar scintigraphy and com-
puted tomographic pulmonary angiography) both of which 
incur an ionizing radiation dose.
5 |  CONCLUSION
DCE 1H‐MRI has previously been used to report on lung 
perfusion defects,38-40 employing T1‐weighted imaging 
to monitor GBCA bolus passage through the pulmonary 
vasculature. The DSC 19F‐MRI approach we present here 
differs from DCE 1H‐MRI in its ability to report on gas 
phase PFP directly adjacent to contrast agent that is present 
within the alveolar microvasculature. This holds potential 
for assessing lung perfusion at the alveolar level, applica-
ble to basic physiology studies concerning gas exchange, 
with scope to develop for use in clinical populations (e.g., 
assessing the suitability for, and response to, long‐term ox-
ygen therapy in patients with emphysema). Moreover, the 
approach is well suited to truly simultaneous assessment 
of alveolar ventilation and perfusion properties. Combined 
assessment of pulmonary ventilation and perfusion has 
previously been reported with 19F‐MRI of inhaled sul-
fur hexafluoride,41 exploiting the accumulation of SF6 in 
regions of low ventilation/perfusion ratio (VA/Q), coupled 
with the ability to measure SF6 partial pressure (sensitive 
to VA/Q) by change to its T1. Tracer‐free methods such as 
Fourier decomposition offer significant scope and appeal 
for assessment of lung function, enabling an indirect but 
entirely noninvasive approach to gauge ventilation and 
perfusion properties over the course of several respira-
tory cycles.33,42,43 Nonetheless, the DSC 19F‐MRI method 
 reported here provides a rapid (single breath‐hold) approach 
that can be readily incorporated into existing 19F‐MR 
ventilation imaging. By its nature, DSC 19F‐MRI of in-
haled PFP will only permit assessment of lung perfusion 
in regions of the lung that are adequately ventilated; yet, 
this provides an opportunity to report specifically on those 
regions of the lung that are directly participating in gas 
exchange (i.e., are both ventilated and perfused), which 
may be of wider clinical significance. Furthermore, studies 
employing dynamic imaging of inhaled PFP have previ-
ously demonstrated the ability for even poorly ventilated 
regions of the lung to exhibit gas wash‐in, albeit at slower 
rates than well‐ventilated regions.8 Thus, with appropriate 
experimental design, this limitation may be confined to re-
gions of the lung where ventilation is truly absent (e.g., 
complete airway obstruction secondary to intrapulmonary 
mass). Further evaluation of this technique against existing 
MRI methods, as well as conventional pulmonary function 
tests, will be critical in assessing its potential to provide 
additional functional information relating to alveolar 
pathophysiology.
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